Joint Transnational Call 2016 (JTC2016)
HCQ4Surfdefect
Among children with interstitial lung diseases (chILD) the surfactant dysfunction disorders play an important role, but no proven treatments are available. During the last 30 years and based on anecdotal reports, hydroxychloroquine, a drug usually used for malaria treatment, has been tried to treat chILD.
The goals of this project are to investigate if the start or the withdrawal of hydroxychloroquine treatment will alter the oxygenation compared to placebo in patients with surfactant dysfunction disorders. Among others, quality of life, and costs will be assessed. The study will be done by teams in Austria, Germany, Italy, Poland, Portugal, Spain and Turkey. We hope to establish a safe and effective way to treat these forms of chILD.
- Griese, Matthias (Coordinator)
Dr. Von Hauner Children’s Hospital, University of Munich [GERMANY] - Moreno Galdó, Antonio
Hospital Universitari Vall d’Hebron [SPAIN] - Krenke, Katarzyna
Medical University of Warsaw [POLAND] - Cutrera, Renato
Bambino Gesù Children Hospital [ITALY] - Kiper, Nural
Hacettepe University, Faculty of Medicine [TURKEY] - Szépfalusi, Zsolt
Medical University of Vienna [AUSTRIA] - Bandeira, Teresa
Centro Hospitalar Lisboa Norte, Hospital de Santa Maria [PORTUGAL] - Kronfeld, Kai
Medical School of the University Mainz [GERMANY]
